JPRN-UMIN000014388已完成未知
A study on the efficacy and safety of ipragliflozin monotherapy or combination therapy under clinical use condition: continuous glucose monitoring and self monitoring of urine glucose - A study on the efficacy and safety of ipragliflozin monotherapy or combination therapy under clinical use condition: continuous glucose monitoring and self monitoring of urine glucose
Kato clinic of Internal medicine0 个研究点目标入组 30 人开始时间: 2014年6月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Type 1 diabetes 2) With severe ketosis, diabetic coma, or precoma 3) With severe infection, pre or post surgery, and serious trauma 4) With moderate or severe renal dysfunction (Serum Creatinin male: >= 1.5 mg/dL, female: >= 1.3 mg/dL) 5) Is receiving SGLT-2 inhibitor, insulin at initiation 6) Is nursing or pregnant or planned to become pregnant 7) Has history of hypersensitivity to ipragliflozin or any other excipient of ipragriflozin 8) Considered as inadequate by the investigator
研究者
相似试验
已完成
不适用
Investigation of the efficacy and safety of ipragliflozin in obese patients with type 2 diabetes undergoing metformin (Met)Type 2 diabetesJPRN-UMIN000014638Association of medical corporation Toyukai, Yutenji Medical Clinic35
已完成
不适用
Investigation of the efficacy and safety of ipragliflozin combination therapy in case of insufficient glycemic control by DPP-4 inhibitorsType 2 diabetesJPRN-UMIN000014790Japan Community Health care Organization Kanazawa Hospital30
已完成
不适用
A randomized and comparative study of ipragliflozin and sitagliptin in patients with type 2 diabetesType 2 diabetesJPRN-UMIN000014738Japan Organaization of Occupational Health and Safety(JOHAS), Yokohama Rosai Hospital120
已完成
不适用
Efficacy and safety of Ipragliflozin in patients with type 2 diabetes who have inadequate glycemic control.Type 2 diabetesJPRN-UMIN000014306akakinen clinic100
尚未招募
不适用
Efficacy and Safety of Ipragliflozin, a selective SGLT2 inhibitor, in type 2 diabetes patients with insulin therapytype 2 diabetesJPRN-UMIN000014968Tokyo Medical University Hospital Division of Diabetes,Metabolism and Endocrinology50